Evotec Reports Significant Progress in Collaboration with Bristol Myers Squibb

Evotec SE has announced meaningful advancements in its strategic partnership with Bristol Myers Squibb. The collaboration focuses on developing a pipeline of molecular glue degraders, yielding performance and program-based payments totaling $75 million to Evotec.

The partnership, initiated in 2018 and expanded in 2022, combines Evotec’s multi-omics screening and analytics with Bristol Myers Squibb’s library of cereblon E3 ligase modulators (CELMoDs™). This collaboration aims to identify degraders targeting high-value oncology targets and other therapeutic areas.

Chief Scientific Officer Dr. Cord Dohrmann highlighted the systematic approach, stating that the pipeline is on track to deliver multiple first-in-class products. The collaboration is expected to continue generating promising molecular glue degraders.